<DOC>
	<DOCNO>NCT00355095</DOCNO>
	<brief_summary>The purpose study determine safety efficacy erythropoietin add-on therapy methylprednisolone subject acute autoimmune optic neuritis .</brief_summary>
	<brief_title>Safety Efficacy Study Erythropoietin add-on Therapy Methylprednisolone Treat Acute Optic Neuritis</brief_title>
	<detailed_description>SUMMARY This study multicenter , double-blind , placebo-controlled , parallel-group study determine safety efficacy erythropoietin ( Epo ) add-on therapy methylprednisolone ( Mpred ) subject acute autoimmune optic neuritis . The primary study endpoint nerve fiber loss optical nerve head determine optical coherence tomography week 4 , 8 , 16 compare baseline . Further study objective include visual acuity , visual field perception , optic nerve atrophy determine magnetic resonance imaging ( MRI ) , recovery visual evoke potential ( VEPs ) . A number 40 subject randomize equal number one two treatment group . Treatment group : Epo placebo administer i.v . three consecutive day . Epo placebo give daily follow application Mpred preferably 8 10 a.m.. Subjects randomize one follow two treatment group dose follow : - Mpred dose 1000 mg per day day 1 - 3 give i.v . infusion AND 3.3 x 10^4 IU recombinant human Epo per day day 1- 3 give i.v . bolus injection . - Mpred dose 1000 mg per day day 1 - 3 give i.v . infusion AND placebo ( normal saline ) day 1 - 3 give i.v . bolus injection . Men woman age 18 50 , inclusive , diagnosed acute unilateral optic neuritis without prior diagnosis multiple sclerosis ( accord McDonald criterion ; Polman et al. , 2005 ) consider inclusion study . Those subject must decrease visual acuity affect eye 0.5 less must sign write informed consent . While safety monitor study , efficacy evaluation do subject complete week 16 . Each subject include study see treat neurologist examine neurologist well examine ophthalmologist . The treat neurologist function primary treat physician conduct subject safety assessment . The examine ophthalmologist examine neurologist conduct evaluation vision/optical nerve head atrophy neurological symptom , respectively , involved aspect patient care . A neurophysiologist perform measurement VEPs . MRIs perform neuroradiologist .</detailed_description>
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>To eligible participate study , candidate must meet following eligibility criterion time randomization : Must give write informed consent authorize release use protect health information ( PHI ) . Must 18 50 year old , inclusive , time informed consent . Must acute unilateral optic neuritis without prior diagnosis MS ( accord McDonald criterion ) . Symptoms related optic neuritis must exist long 10 day prior inclusion . Must normal visual acuity eye history optic neuritis . Must decrease visual acuity affect eye 0.5 less screening . Candidates exclude study follow exclusion criterion exist time randomization : Medical history : Abnormal laboratory result clinical sign indicative significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , gastrointestinal , dermatologic , psychiatric , renal , neurological ( MS ) , and/or major disease . History prior optic neuritis affect nonaffected eye . History squint amblyopia either side . Hyperopia &gt; 3dptr either side . Myopia &lt; 5dptr either side . Astigmatism &gt; 2dptr either side . Horizontal cup disc ratio &gt; 0.5 either side . Retinal nerve fiber layer thickness outside normal value ( respect OCT data base ) . Ocular disease effect visual acuity visual field ( cataract , glaucoma , maculadegeneration , diabetic retinopathy , retinal heredodegeneration others ) . History elevate blood pressure . Systolic blood pressure &gt; 159 mmHg , diastolic blood pressure &gt; 99 mmHg screen examination . History thromboembolic event . Frequent thromboembolic event 1st grade family member . Significant surgery within 4 week prior randomization . History severe allergic anaphylactic reaction administration Epo . History malignancy . History seizure . Tuberculosis ongoing unknown activity . Acute gastrointestinal ulceration within last three month . Acute virus , bacterial fungus infection . Infection HIV , HBV , HCV . History colitis ulcerosa , diverticulitis , acute enteroanastomosis . Severe osteoporosis . Active immunization within 2 week prior inclusion . Diagnosis phenylketonuria . Implanted cardiac pacemaker non MRIcompatible metallic body implant . History drug alcohol abuse ( define investigator ) within 2 year prior randomization . Any following abnormal blood test screen : alanine transaminase/serum glutamatepyruvate transaminase ( AST/SGPT ) , aspartate transaminase/serum glutamicoxaloacetic transaminase ( AST/SGOT ) , gammaglutamyltransferase ( GGT ) , serum creatinine &gt; 2 time upper limit normal ; hematocrit &gt; upper limit normal . Treatment history Prior treatment cyclosporine , mitoxantrone , methotrexate , cyclophosphamide immunosuppressive agent . Treatment corticosteroid Epo within 30 day prior randomization . Miscellaneous Female subject consider become pregnant study . Female subject currently pregnant breastfeeding . Previous participation study investigational drug study within last four week . Current enrollment investigational drug study . Unwillingness inability comply requirement protocol include presence condition ( physical , mental , social ) likely affect subject 's ability comply protocol . Any reason , opinion investigator , subject determine unsuitable enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>add-on Therapy</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>methylprednisolone</keyword>
	<keyword>autoimmune optic neuritis</keyword>
</DOC>